AU2002214096A1 - Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy - Google Patents

Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

Info

Publication number
AU2002214096A1
AU2002214096A1 AU2002214096A AU1409602A AU2002214096A1 AU 2002214096 A1 AU2002214096 A1 AU 2002214096A1 AU 2002214096 A AU2002214096 A AU 2002214096A AU 1409602 A AU1409602 A AU 1409602A AU 2002214096 A1 AU2002214096 A1 AU 2002214096A1
Authority
AU
Australia
Prior art keywords
treating
diabetic retinopathy
apoptosis inhibitors
preventing diabetic
pericyte apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214096A
Inventor
Ulriche Denis
Michel Lagarde
Marc Lecomte
Clarisse Paget
Nicolas Wiernsperger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Merck Sante SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
LIPHA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, LIPHA SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU2002214096A1 publication Critical patent/AU2002214096A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
AU2002214096A 2000-10-24 2001-10-24 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy Abandoned AU2002214096A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0013640A FR2815541B1 (en) 2000-10-24 2000-10-24 USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY
FR00/13640 2000-10-24
PCT/FR2001/003306 WO2002034201A2 (en) 2000-10-24 2001-10-24 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

Publications (1)

Publication Number Publication Date
AU2002214096A1 true AU2002214096A1 (en) 2002-05-06

Family

ID=8855696

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214096A Abandoned AU2002214096A1 (en) 2000-10-24 2001-10-24 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

Country Status (9)

Country Link
US (1) US8119609B2 (en)
EP (2) EP2359840A1 (en)
JP (1) JP4387101B2 (en)
AU (1) AU2002214096A1 (en)
BR (1) BR0114759A (en)
CA (1) CA2428907A1 (en)
FR (1) FR2815541B1 (en)
NO (1) NO20031806D0 (en)
WO (1) WO2002034201A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815541B1 (en) 2000-10-24 2008-02-29 Lipha USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY
AU2003209297A1 (en) * 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
CA2526493A1 (en) * 2003-05-22 2004-12-02 Theraptosis S.A. Means for preventing and treating cellular death and their biological applications
EP1740614A2 (en) * 2004-04-30 2007-01-10 Theraptosis S.A. Caspase-2 inhibitors and their biological applications
FR2878522B1 (en) 2004-12-01 2008-04-18 Merck Sante Soc Par Actions Si NEW SPECIFIC INHIBITORS OF CASPAS-10
FR2884820B1 (en) 2005-04-25 2007-07-27 Merck Sante Soc Par Actions Si NEW SPECIFIC INHIBITORS OF CASPASE-10
EP1884234B1 (en) * 2005-05-17 2012-07-18 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for corneal and conjunctival disorder
US20070098709A1 (en) * 2005-06-29 2007-05-03 Gaetano Barile Methods for treating and preventing diabetic retinopathy
JP2010507387A (en) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
CN101940571A (en) * 2007-04-13 2011-01-12 南方研究所 Anti-angiogenic agent and using method
RU2460526C2 (en) * 2007-05-25 2012-09-10 Сантен Фармасьютикал Ко., Лтд. Prophylactic and therapeutic drug for age-related macular degeneration
JP5646997B2 (en) 2007-10-03 2014-12-24 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Novel siRNA structure
KR20100124756A (en) * 2008-02-28 2010-11-29 산텐 세이야꾸 가부시키가이샤 Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder
DK2352493T3 (en) * 2008-11-03 2014-02-10 Giuliani Spa THERAPEUTIC, DIETETIC OR COSMETIC APPLICATION OF COMPOUNDS WITH SPECIFIC ANTI-OPTOTIC ACTIVITY AGAINST CASPASE-3 AND COMPOSITIONS CONTAINING THESE COMPOUNDS
DK2442645T3 (en) * 2009-06-15 2014-11-24 Encore Health Llc choline
TN2010000251A1 (en) * 2010-06-03 2011-11-11 Rekik Raouf N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR
WO2018013519A1 (en) * 2016-07-11 2018-01-18 The Trustees Of Columbia University In The City Of New York Ocular delivery of cell permeant therapeutics for the treatment of retinal edema
WO2018085565A2 (en) * 2016-11-03 2018-05-11 Helix Biomedix, Inc. Short bioactive peptides blocking activity of advanced glycation end products, compositions, and methods of use
WO2019089993A1 (en) * 2017-11-02 2019-05-09 Living Cell Technologies New Zealand Limited Pericyte protective agents for neurological disorders including neurodegenerative diseases, central nervous system diseases and others

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789951A (en) * 1993-06-03 1995-04-04 Sterling Winthrop Inc Interleukin-1 beta transfer enzyme inhibitor
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
RU2070010C1 (en) * 1993-08-31 1996-12-10 Эдуард Сергеевич Аветисов Agent for antioxidant protection of eye media and tissues
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
WO1995017900A1 (en) * 1993-12-30 1995-07-06 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
JPH08175993A (en) * 1994-12-21 1996-07-09 Green Cross Corp:The Antioxidizing agent
JPH09278652A (en) 1996-04-05 1997-10-28 Sumitomo Pharmaceut Co Ltd Retinal disease-treating preparation
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
DE59712694D1 (en) * 1997-04-18 2006-08-24 Fritz Stanislaus STABILIZED MEDICAMENT CONTAINING CYSTEINYL DERIVATIVES
WO1999002174A1 (en) * 1997-07-11 1999-01-21 Ludwig Institute For Cancer Research Non-human pdgf-b-deficient transgenic animals with reduced or non-existent numbers of pericytes
CN1324234A (en) * 1998-09-25 2001-11-28 格利科克斯有限公司 Fructosamine oxidase: antagonists and inhibitors
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2000047218A1 (en) * 1999-02-11 2000-08-17 The Trustees Of The University Of Pennsylvania Regulation of photoreceptor degeneration
DE19915465A1 (en) 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
EP1177168B1 (en) * 1999-04-09 2007-05-30 Cytovia, Inc. Caspase inhibitors and the use thereof
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
WO2000074672A1 (en) * 1999-06-09 2000-12-14 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
AU1920501A (en) * 1999-12-03 2001-06-12 Alcon Universal Limited The use of caspase 9 inhibitors to treat ocular neural pathology
EP1317454B1 (en) * 2000-09-13 2011-05-25 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2002224403A1 (en) * 2000-10-13 2002-04-22 Entremed, Inc Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
FR2815541B1 (en) 2000-10-24 2008-02-29 Lipha USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY

Also Published As

Publication number Publication date
JP2004512287A (en) 2004-04-22
FR2815541B1 (en) 2008-02-29
BR0114759A (en) 2003-10-07
EP1343491A2 (en) 2003-09-17
WO2002034201A2 (en) 2002-05-02
US8119609B2 (en) 2012-02-21
WO2002034201A3 (en) 2003-03-27
JP4387101B2 (en) 2009-12-16
NO20031806D0 (en) 2003-04-23
FR2815541A1 (en) 2002-04-26
US20030216290A1 (en) 2003-11-20
EP2359840A1 (en) 2011-08-24
CA2428907A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
AU2002214096A1 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
US5919813C1 (en) Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2002361846A1 (en) Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
PL365520A1 (en) Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2001282886A1 (en) Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
HK1094909A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU2001274817A1 (en) Agents that modulate dna-pk activity and methods of use thereof
AU2002367172A1 (en) 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002247208A1 (en) Selective pde3b inhibitors and use of the same in therapy
AU2208401A (en) Inhibitors of complement activation, their preparation and use
AU5463099A (en) Inhibitors of redox signaling and methods of using same
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002227123A1 (en) Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU3270301A (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
AU2001262939A1 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted